Lumida
/RCKT
⌘K
Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

RCKT
$3.35USD-3.74%-0.13 today

MARKET CAP

367.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $4

52W RANGE

$3
$5

AI Summary

Stalk
StalkMedium

RCKT is in a Stage 2 advance after clearing the 3.55 resistance on strong volume. Price is now extended above rising EMAs with extreme overbought readings on RSI and Options Score. While the medium-term trend remains bullish following the Momentum Breakout, timing is unfavorable until a pullback into the 9/21 EMA zone and prior breakout level near 3.55 offers cleaner entry.

  • Anticipated resumption of Danon disease trial after FDA alignment
  • Low-dose cohort showed NYHA class improvements, advancing to Phase 2
  • Negative earnings yield and poor profitability raise operational sustainability concerns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020TREND
Sales, Adj.$0$0
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.$0$0
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.$-75.5M$-133.2M
YoY %-76.4%
Margin %
EV / EBITDA-13.2x-21.2x
EBIT$-75.9M$-134.3M
YoY %-76.9%
Margin %
EV / EBIT-13.1x-21.1x
Net Income$-77.3M$-139.7M
YoY %-80.8%
Net Margin
EPS (GAAP)-$1.58-$2.52
YoY %-59.5%